SMAD4 and neoplasm: There appears to be less consistency in the observation of changes in the CDKN2A and SMAD4 tumour suppressor genes, with estimates for their functional loss ranging from 15% to 60%, perhaps contributed by different assessment technologies and differences between the analysed populations [7,8,9,10,11,12,13,14,15].